This document discusses guidelines for single unit red blood cell transfusions based on Patient Blood Management Guidelines. It provides 3 key reasons why excessive transfusion is problematic: 1) each transfusion increases the risk of nosocomial infection and other morbidities, 2) higher transfusion requirements are associated with more clinical complications, and 3) transfusion associated circulatory overload is a high risk adverse effect. The document emphasizes transfusing one unit at a time and reassessing the patient before additional units, in order to follow a more restrictive approach and reduce risks whenever possible based on the patient's clinical status rather than hemoglobin levels alone.
These guidelines are very important in cardiac surgery. Tranfusion triggers, perfusion interventions,blood salvage,blood products all are described in great detail.
These guidelines are very important in cardiac surgery. Tranfusion triggers, perfusion interventions,blood salvage,blood products all are described in great detail.
Jehowah's witnesses and blood conservation strategies by Dr.Minnu M. PanditraoMinnu Panditrao
dr. Mrs. Minnu M. Panditrao explains the problems faced by anesthesiologists in anesthetising the Jehowah's Witness patients because of their beliefs. Ina ddition she also discribes various strategies of Blood conservation.
Effect of restrictive versus liberal transfusion strategies on outcomes in pa...Mohd Saif Khan
Restrictive red cell transfusion policies are recommended as safe for most hospital patients with anaemia. Uncertainty exists for patients with cardiovascular disease, whose hearts may be more susceptible to limited coronary oxygen supply.
Jehowah's witnesses and blood conservation strategies by Dr.Minnu M. PanditraoMinnu Panditrao
dr. Mrs. Minnu M. Panditrao explains the problems faced by anesthesiologists in anesthetising the Jehowah's Witness patients because of their beliefs. Ina ddition she also discribes various strategies of Blood conservation.
Effect of restrictive versus liberal transfusion strategies on outcomes in pa...Mohd Saif Khan
Restrictive red cell transfusion policies are recommended as safe for most hospital patients with anaemia. Uncertainty exists for patients with cardiovascular disease, whose hearts may be more susceptible to limited coronary oxygen supply.
Blood transfusion is a complex activity in healthcare, constitutes an important part of various treatment protocols. Thus the indications for ordering blood must be fully justified to avoid over or misusage of this resource. In a 5 year retrospective study, details of patient’s diagnosis and indications for transfusion are correlated with whole blood and components transfused from the blood bank data base in SAQR Hospital, in Ras Al Khaimah UAE. It was found that 7,045 blood units which were transfused, maximum blood was supplied to surgical wards; most common indications for transfusion were injuries during road traffic accidents, orthopedic surgeries and cardiovascular surgeries. Nearly half (52%) of all blood was given to female recipients. UAE nationals received the maximum units of blood; most prevalent blood group among blood transfusion recipients was O +ve. Major usage of blood products transfused were packed RBC’s. The study concludes that regular assessment of blood component usage followed by academic sessions for clinicians is recommended for effective and efficient use of available blood to patients in a life-threatening situation.
Practice of Indian Physicians Towards Use of Calcium Channel Blockers in the ...Mahdy Ali Ahmad Osman
A journal club on the Practice of Indian Physicians Towards Use of Calcium Channel Blockers in the Management of
Hypertension A Paper Based Questionnaire Survey, research.
Advanced Lab Analytics for Patient Blood Management ProgramsViewics
Reports indicate that 30 – 70% of blood transfusions are inappropriate. Inappropriate blood transfusions put patients at increased risk of post-surgical infections, multi-system organ failure, longer hospital stays, and higher mortality rates. The transfusion guidelines most clinicians learned in their training are now outdated. As such, blood transfusion practices vary widely, and overutilization remains a major quality and cost problem.
Patient Blood Management (PBM) programs are designed to optimize the use of transfusions through a team-based approach, evidence-based guidelines, and algorithms that together guide decisions regarding specifically which patients and clinical procedures warrant blood products, and how much to transfuse. PBM programs have been quite successful in improving patient morbidity and mortality outcomes and generating millions of dollars in savings for hospitals.
Laboratory analytics can be an effective means of instituting restrictive transfusion programs, and advanced lab analytics can be critical in implementing PBM programs, as lab testing and tracking blood usage is central to decision making, changing behavior, and improving performance.
Watch a presentation by Dr. Eleanor Herriman, Chief Medical Informatics Officer at Viewics. She unveils a new suite of advanced analytics tools that support PBS and other restrictive blood management programs, enabling health systems to better leverage their valuable lab medicine assets and fully integrate this key service line into these programs.
You’ll learn:
• How inappropriate blood transfusions are burdening our healthcare system, and the need for better utilization management tools
• New guidelines restricting red blood cell transfusions
• The role of advanced lab analytics in PBM programs
• How Viewics is leveraging advanced lab analytics to help health systems more easily and cost-effectively implement PBM programs
Major surgery is a considerable physiologic insult that can be
associated with significant morbidity and mortality. The prevention of perioperative morbidity is a determining factor in providing high-quality in health care, since the occurrence of postoperative complications adversely affects postoperative survival and increase healthcare costs
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
2. WHY GIVE 2 WHEN 1 WILL DO….
TOWARD A MORE RESTRICTIVE RED CELL
TRANSFUSION APPROACH
Objectives
Discuss Patient Blood Management Guidelines
Discuss the reasons for single unit blood
transfusions.
To provide resource material in the form of a
wikispace and hard copy for the doctor to refer to.
3. WHY GIVE 2 WHEN 1 WILL DO…
PATIENT BLOOD MANAGEMENT GUIDELINES
(PBM)
What are the Patient Blood Management guidelines?
Evidence-based blood management guidelines that are a
summary of recommendations and practice points
developed by the National Blood Authority and is based on
systematic reviews. The Medical model is the third in a
series of six modules
Why have a Patient Blood Management Guidelines?
The Patient Blood Management Guidelines were introduced
in 2012 to improve clinical outcomes by avoiding
unnecessary exposure to blood components.
Transfusion is a live tissue transplant and not without
associated risks
4. WHY GIVE 2 WHEN 1 WILL DO…
PATIENT BLOOD MANAGEMENT GUIDELINES
(PBM)
Why have a Patient Blood Management Guidelines?
Blood products are a scarce resource and will only
become more scarce with the ageing population.
Economic costs – about $1 Billion per year in plus the
added costs.
http://www.blood.gov.au/pbm-module-3
5. PBM MODULE 3- SYSTEMATIC REVIEW
QUESTIONS
Box 2.1 Systematic review questions
Questions 1 – 5 are relevant to all six modules of these guidelines; Question 6 is specific to
medical transfusion (i.e. to this module).
• Question 1 – In medical patients, is anaemia an independent risk factor for
adverse outcomes? (Aetiological question)
• Question 2 – In medical patients, what is the effect of RBC transfusion on
patient outcomes? (Interventional question)
• Question 3 – In medical patients, what is the effect of non-transfusion
interventions to increase Hb concentration on morbidity, mortality and need for
RBC blood transfusion? (Interventional question)
• Question 4 – In medical patients, what is the effect of
FFP, cryoprecipitate, fibrinogen concentrate, and/or platelet transfusion on
patient outcomes? (Interventional question)
• Question 5 – In medical patients, at what INR (PT/APTT) for FFP, fibrinogen
level for cryoprecipitate and platelet count for platelets concentrates should
patients be transfused to avoid risks of significant adverse events?
(Interventional and Prognostic question)
• Question 6 – In specific regularly and chronically transfused patients, at what
Hb threshold should patients be transfused to avoid adverse outcomes?
(Interventional question)
APTT, activated partial thromboplastin time; FFP, fresh frozen plasma; Hb, haemoglobin;
INR, international
6. WHY GIVE 2 WHEN 1 WILL DO…PATIENT
BLOOD MANAGEMENT GUIDELINES
www.blood.gov.au
www.blood.gov.au/pbm-guidelines
7. WHY GIVE 2 WHEN 1 WILL DO…SINGLE
UNIT TRANSFUSION
WHO
The
stable, normovolaemic
adult inpatient who does
NOThave clinically significant
bleeding with symptoms of
anaemia
Haemoglobin as defined in the
Patient Blood Management
Guidelines www.blood.gov.au/patient-bloodmanagement
8. WHY GIVE 2 WHEN 1 WILL DO
This does not include the chronically
transfused such as patients with MDS.
According to the Patient Blood Management
Guidelines;
“…there is no evidence to guide clinicians on the
Hb threshold for transfusion in patients with
MDS and chronic anaemia. Further studies are
needed to assess the benefit of transfusion in this
population”
http://www.blood.gov.au/pbm-module-3
9. “EVERY ONE MATTERS”
WHAT
Transfuse one unit, then reassess the
patient for clinical symptoms before
transfusing another
Every unit is a new clinical
decision
Base decision on patient
symptoms, not only on
haemoglobin
10. SINGLE UNIT TRANSFUSION
WHY
It is important to align practice with the
national Patient Blood Management
Guidelines
Transfusion
may be an independent risk
factor for increased morbidity, mortality and
length of stay.
Potential harm from transfusion is dose
dependent
Transfusion is a live tissue transplant
The British Committee for Standards in Haematology (2012). Guidelines on the Administration of Blood Components. Addendum to
11. THREEREASONS WHY EXCESSIVE
TRANSFUSION IS A PROBLEM
Reason 1:
Each transfusion increases the risk of
nosocomial infection increases other morbidities
Analysis of 11,963 patients after CABG surgery
showed that perioperative RBC transfusion was
associated with a dose-dependent increased risk of
postoperative cardiac complications, serious
infection, renal failure, neurologic
complications, overall morbidity, prolonged
ventilator support, and in-hospital mortality.
Koch CG et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery
bypass grafting. Crit Care Med 2006, 34: 1608-1616.
12. THREEREASONS WHY EXCESSIVE
TRANSFUSION IS A PROBLEM
Reason 2:
Transfusion requirements after cardiac surgery
(TRACS) study prospectively demonstrated the
safety of a restrictive strategy of red blood cell
(RBC) transfusion in patients undergoing
cardiac surgery. Also reported: the higher the
number of transfused RBC, the higher was the
number of clinical complications.
Hajjar LA et al. Transfusion requirements after cardiac surgery: the TRACS randomised controlled trial.
JAMA, 304:1559-1567.
13. THREEREASONS WHY EXCESSIVE
TRANSFUSION IS A PROBLEM
Reason 3:
Transfusion associated circulatory overload
(TACO) is among the high risk adverse
effects of red cell transfusion (up to 1 in 100
per unit transfused).
National Blood Authority, 2012. Patient Blood Management Guidelines: Module 2 - Perioperative.
Appendix B, Table B.2.Transfusion Risks in perspective.
14. WHY GIVE 2 WHEN 1 WILL DO….
TOWARD A MORE RESTRICTIVE TRANSFUSION
APPROACH
How are these guidelines relevant to you?
Practice
Points 4.4 (Red Cells and Cancer)
RBC
transfusion should not be dictated by a Hb concentration
alone, but also base on the assessment of the clinical status of
the patient
When
indicated, the transfusion of a single unit of red
cells, followed by clinical reassessment to determine the need
for further transfusion, is appropriate.
http://www.blood.gov.au/pbm-module-3
15. HOW IS THIS RELEVANT TO YOU IN THE
ONCOLOGY/HAEMOTOLOGY SETTING?
Refer to the Handouts from the Patient Blood
Management Guidelines;
1. Effect of anaemia on outcomes (3.1.4)
2.Effect of RBC on outcomes (3.2.4)
3. What is the effect of non-transfusion interventions
to increase Hb concentration. (3.3.1)
Red cell Transfusion in the chronically transfused
(3.3.1)
Myleodysplastic syndrome (3.3.6)
Assessment of patient after red blood cell transfusion (p.68)
16. SINGLE UNIT TRANSFUSION GUIDELINE
Benefits: Safer, evidence based transfusion
PLUS:
Reduced risk of non-infectious adverse events
Reduced demand on limited blood supply
Reduced risk from new infectious agents
Every ONE matters
17. RESEARCH QUESTIONS AND OTHER
THOUGHTS….
The NBA states that there is currently no strong
evidence –base underpinning treatment and
dosing with blood products.
The number 1 research priority area identified by the
NBA is to ensure the use of blood and blood products
is appropriate, eg in chronically transfused
patients, there is currently no evidence to guide
clinicians.
Patient Education….to educate and shift patient
thinking that they will automatically be transfused
with two units (or three or four…)
Introductory Slide – Establish context of single unit transfusion policy in over-arching restrictive transfusion and patient blood management framework.The catch phrase “Every ONE matters” is used in these slides. You may wish to substitute it for another phrase e.g. “ONE bag is best the reassess” or “Be SINGLE minded”
These are the research questions that guided the sytematic review searches.
Background: Specific patient group – excludes actively bleeding patient, and patient in theatre.Emphasis on individual patient assessment for each unit – NOT transfusion according to Hb alone, or traditional request for 2 units. Evidence based Patient Blood Management Guidelines: Module 3 - Medical and Module 4 - Critical care patients available to guide appropriate Hb levels.The evidence-based Patient blood Management Guidelines4,5 state the haemoglobin transfusion thresholds as: Hb concentration <70 g/L, RBC transfusion may be associated with reduced mortality and is likely to be appropriate. However, transfusion may not be required in well compensated patients or where other specific therapy is available. Hb concentration of 70 – 100 g/L, RBC transfusion is not associated with reduced mortality. The decision to transfuse patients (with a single unit followed by reassessment) should be based on the need to relieve clinical signs and symptoms of anaemia, and the patient’s response to previous transfusions. No evidence was found to warrant a different approach for patients who are elderly or who have respiratory or cerebrovascular disease. Hb concentration >100 g/L, RBC transfusion is likely to be unnecessary and is usually inappropriate. Transfusion has been associated with increased mortality in patients with ACS. For patients with acute coronary syndrome (ACS), the evidence-based Patient Blood Management Guidelines4,5 state transfusion haemoglobin thresholds as:In patients with ACS and a Hb concentration <80 g/L, RBC transfusion may be associated with reduced mortality and is likely to be appropriate.In patients with ACS and a Hb concentration of 80 – 100 g/L, the effect of RBC transfusion on mortality is uncertain and may be associated with an increased risk of recurrence of MI. Any decision to transfuse should be made with caution and based on careful consideration of the risks and benefits.In ACS patients with a Hb concentration >100 g/L, RBC transfusion is not advisable because of an association with increased mortality.
In patients with MDS who are chronically transfused need individualised decision-making, taking into consideration clinical factors, anemai-related symptoms, funtional status and patients response to previuos transfusions.
National Safety and Quality in Health(Standard 7: Blood and Blood Products) require blood and blood product policies and procedures to be consistent with national evidence based guidelines for pre-transfusion practices, prescribing and clinical use of blood and blood products.Recent scientific literature supports transfusion is an independent risk of increased morbidity, mortality and hospital length of stay. The risk of harm is dose dependent – every unnecessary unit transfused represents an imbalance towards risk, not benefit.The ageing population represents BOTH an increasing demand for blood products, and a reduction in the available eligible blood donors.The cost of blood transfusion is many multiples of the cost of the product itself (estimated at 4.8 times cost of unit). Significant and growing impact on health budgets. Apart from in the actively bleeding patient, there is a lack of evidence for benefit of red blood cell transfusion.
The risk and benefit equation must be considered for each unit of blood transfused. There is a lot of evidence of risk, and harm from blood, but very little evidence of benefit in the non-bleeding patient.Transfusion is an independent risk for nosocomial infection, increased morbidity, mortality and increased length of hospital stay.The ageing population will increase the demand on blood products, while the pool of eligible donors will decrease.While blood is extremely safe from the known infectious agents, the threat of new, unknown or re-emerging agents must be considered.CONCLUSION:The single unit transfusion guideline will align practice with evidence, and reduce potential harm from unnecessary transfusion.